SGLT-2 inhibition leads to only a modest reduction in haemoglobin A1c when used for the management of T2D; however, it still leads to a significant reduction in cardiovascular outcomes in these patients, which indicates that adverse cardiovascular events in T2D may not be solely mediated by dysglycaemia. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.